NCT02857972

Brief Summary

General objective: To assess the preference and performance in terms of satisfaction and acceptability as well as safety profile of a novel innovative design of menstrual hygiene device (Wondaleaf®) during the night for menstruating women by comparing it to prior experience of the usual hygienic product for menstrual control, i.e. sanitary pads. Specific objectives:

  • To determine the preference of participants between Wondaleaf® and usual sanitary pads as a night use menstrual hygiene product.
  • To determine the satisfaction of participants towards Wondaleaf® and usual sanitary pads as a night use menstrual hygiene product.
  • To determine the acceptability of participants towards Wondaleaf® as a night use menstrual hygiene product.
  • To determine the safety profile of the Wondaleaf®.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 2, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 5, 2016

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

February 3, 2017

Status Verified

February 1, 2017

Enrollment Period

5 months

First QC Date

August 2, 2016

Last Update Submit

February 1, 2017

Conditions

Keywords

Menstruation, Female Barrier, Sanitary pads

Outcome Measures

Primary Outcomes (1)

  • Preference

    Wondaleaf® usage during the night is better; same or worse as compared to usual sanitary pad usage during menstruation.

    every night for one cycle of menstruation, an average of 5 days

Secondary Outcomes (3)

  • Satisfaction

    every night for one cycle of menstruation, an average of 5 days

  • Acceptability

    every night for one cycle of menstruation, an average of 5 days

  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    every night for one cycle of menstruation till 3 months after last usage of investigational device

Study Arms (1)

Wondaleaf®

EXPERIMENTAL

This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.

Device: Wondaleaf®

Interventions

Use of Wondaleaf® during menstruation every night in one menstrual cycle.

Also known as: Female Barrier Film
Wondaleaf®

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women within ages of 18 to 45 years old with good health and regular menstrual cycles with last menstrual cycle occurred within 5 weeks of enrolment; subjects can be rescreened after completion of menstrual cycle
  • Women who use sanitary pads as their only menstrual hygiene product.
  • Women who agree to use only the study menstrual hygiene device and not sanitary pads or other menstrual hygiene products for menstruation during the night time of study duration.
  • Women who are able to understand instructions for correct use of study menstrual hygiene product (i.e. the investigational device).
  • Literate women who can complete the study questionnaire on their own in a language of their choice which are English, Malay and Chinese; and attending all study visits.

You may not qualify if:

  • Known history of vaginal or uterine infection(s), and/or urinary tract infections; these subjects can be rescreened after 14 days after successful treatment.
  • Ongoing or past history of sexually transmitted disease, pelvic inflammatory disease, and/or injuries to the pelvis requiring surgical intervention and/or pelvic floor physiotherapy.
  • Female subject who is pregnant (established by urinary pregnancy test).
  • Sensitivity or allergy to polyurethane and acrylic adhesive hypoallergenic.
  • Staff who work directly under the investigators and/or employed directly by the device manufacturers, sponsor and study team.
  • Moving outside Sibu area during study period and have difficulty to return for Visit 2.
  • Female subjects who have menopause (absence of menstruation for more than 6 months in female) or any other circumstances that cause secondary amenorrhea (absence of menstruation for more than 6 months in a normal female of reproductive age that is not due to pregnancy) such as side effect from hormonal contraceptive.
  • Use any medications or preparation applied topically to the perineum or intravaginally to the genitalia but subjects can be rescreened 14 days after the recovery if the application is for acute illness.
  • Use of any medications which known to influence menstruation or study results for any reasons within 14 days, 30 days before Visit 1 and during the intended study duration.
  • Subject participating in another clinical study involving menstrual hygiene device.
  • Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as axillary / tympanic / rectal temperature ≥ 38°C. Subjects can be rescreened 14 days after the recovery;
  • Blood dyscrasias, bleeding disorder, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems;
  • Presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system(s) or psychiatric disease or other conditions that may interfere with the health conditions (such as in case the women subject become pregnant), or would place the subjects at increased risk, as determined by the investigator(s).
  • Significant is defined as any disease/condition that, in the opinion of the researcher, would put the subject's safety at risk through study participation, or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sibu Hospital

Sibu, Sarawak, 96000, Malaysia

Location

Study Officials

  • Teck Hock Toh

    Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia

    PRINCIPAL INVESTIGATOR
  • Vivian Wee Yen Tan

    Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 2, 2016

First Posted

August 5, 2016

Study Start

May 1, 2016

Primary Completion

October 1, 2016

Study Completion

December 1, 2016

Last Updated

February 3, 2017

Record last verified: 2017-02

Locations